Inhibition by probucol of interleukin 1 secretion and its implication in atherosclerosis

Ku, George; Doherty, Niall S.; Wolos, Jeffrey A.; Jackson, Richard L.; Schmidt, Lisa; Hendricks, Deborah

doi:10.1016/s0002-9149(88)80057-2

Cited by 100 publications

(30 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The chemotactic effect described here may, therefore, be relevant not only in the initial stages of lesion formation but throughout the history of the lesion. IL-1 has been demonstrated to be a chemoattractant for T cells (23,24) and Ox-LDL has been shown to increase the secretion of IL-1 (25,26). Thus, there could be an indirect facilitation of T cell recruitment by Ox-LDL in addition to the direct effect demonstrated here.…”

Section: Resultsmentioning

confidence: 61%

Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes.

McMurray¹,

Parthasarathy²,

Steinberg³

1993

J. Clin. Invest.

245

113

View full text Add to dashboard Cite

Oxidatively modified low density lipoprotein (Ox-LDL) is a known chemoattractant for monocytes. Here we demonstrate, using a modified Boyden chamber assay, that human peripheral blood T lymphocytes, but not B lymphocytes, also respond chemotactically to Ox-LDL, showing a threefold increase over control and an optimum response at 10 ;tg/ml. Copper and endothelial cell-oxidized LDL and #l-VLDL were used and gave similar results. The activity was not chemokinetic and native LDL possessed no chemoattractant activity. The chemoattractant activity was found to reside in the lipid fraction of Ox-LDL. Lysophosphatidylcholine is a major phospholipid component of Ox-LDL and is known to be chemotactic for monocytes. We show that lysophosphatidylcholine is also chemotactic for T lymphocytes with a maximal fourfold increase at 10 MM. Nonmetabolizable analogues of lysophosphatidylcholine had no such chemotactic effect. Thus, Ox-LDL, by virtue of its lysophosphatidylcholine content, may contribute to the recruitment of both T lymphocytes and monocytes into developing atherosclerotic lesions. (J. Clin. Invest. 1993. 92:1004-1008

show abstract

Section: Resultsmentioning

confidence: 61%

Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes.

McMurray¹,

Parthasarathy²,

Steinberg³

1993

J. Clin. Invest.

245

113

View full text Add to dashboard Cite

show abstract

“…It has been demonstrated 5) that lipid oxidation products can alter growth factor production, which could influence smooth muscle cell proliferation. Oxidized low density lipoprotein (LDL) has been shown 6) to be a chemoattractant for smooth muscle cells and a stimulant of smooth muscle cell proliferation.…”

Section: Discussionmentioning

confidence: 99%

An Experimental Model of Tumor Dormancy Therapy for Advanced Head and Neck Carcinoma

Nishimura

Yanoma

Satake

et al. 2000

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

An experimental model of tumor dormancy therapy for advanced head and neck carcinoma was developed. After transplantation of KB cells into nude mice, the mice were given tiracoxib, a selective cyclooxygenase (COX)-2 inhibitor, probucol, an antioxidant, and S-1, an oral pro-drug of 5-fluorouracil (5-FU), or combinations of two of them. The combined administration of tiracoxib with probucol significantly inhibited the tumor growth. The angiogenesis in this group was markedly reduced. Tiracoxib and probucol did not affect the intratumoral concentration of 5-FU when coadministered with S-1. The combined use of tiracoxib and probucol is thus a candidate for use in maintenance therapy after the primary therapy for patients with advanced head and neck carcinoma.

show abstract

“…By ultimately limiting smooth muscle cell contraction, collagen formation and cross-linking, and endothelial dysfunction, probucol may have modified vascular remodeling and allowed greater vessel enlargement. Specific inhibition by probucol of the secretion of interleukin-1 22 may also have decreased secretion of metalloproteinases 23 and modified matrix remodeling.…”

Section: Discussionmentioning

confidence: 99%

Effects of Probucol on Vascular Remodeling After Coronary Angioplasty

et al. 1999

View full text Add to dashboard Cite

Background-We have shown that probucol reduces restenosis after balloon angioplasty. Whether probucol acted via prevention of neointimal formation or improvement in vascular remodeling could not be addressed by angiography and required the use of intravascular ultrasound (IVUS). Methods and Results-Beginning 30 days before angioplasty, 317 patients were randomly assigned to receive probucol, multivitamins, combined treatment, or placebo. Patients were then treated for 6 months after angioplasty. IVUS examination was performed immediately after angioplasty and at follow-up in 94 patients (111 segments). The cross section selected for serial analysis was the one at the angioplasty site with the smallest lumen area at follow-up. In the placebo group, lumen area decreased by Ϫ1.21Ϯ1.88 mm 2 at follow-up, and wall area and external elastic membrane (EEM) area increased by 1.50Ϯ2.50 and 0.29Ϯ2.93 mm 2 , respectively. Change in lumen area, however, correlated more strongly with the change in EEM area (rϭ0.53, Pϭ0.002) than with the change in wall area (rϭϪ0. 13, Pϭ0.49

show abstract

Inhibition by probucol of interleukin 1 secretion and its implication in atherosclerosis

Cited by 100 publications

References 14 publications

Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes.

Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes.

An Experimental Model of Tumor Dormancy Therapy for Advanced Head and Neck Carcinoma

Effects of Probucol on Vascular Remodeling After Coronary Angioplasty

Contact Info

Product

Resources

About